Quantitative disease, drug, and trial models.
Quantitative disease-drug-trial models allow learning from prior experience and summarize the knowledge in a ready to apply format. Employing these models to plan future development is proposed as a powerful solution to improve pharmaceutical R&D productivity. The disease and trial models are, to a large extent, independent of the product, but the drug model is not. The goals are to apply the disease and trial models to future development and regulatory decisions, and publicly share them. We propose working definitions of these models, describe the various subcomponents, provide examples, and discuss the challenges and potential solutions for developing such models. Building useful disease-drug-trial models is a challenging task and cannot be achieved by any single organization. It requires a consorted effort by industry, academic, and regulatory scientists. We also describe the strategic goals of the FDA Pharmacometrics group.
Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland 20993-0002, USA. jogarao.gobburu@fda.hhs.gov
Jogarao V S
JV
Gobburu
Lawrence J
LJ
Lesko
D000818:Animals; D017326:Clinical Trials, Phase III as Topic; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D004345:Drug Industry; D004358:Drug Therapy; D006801:Humans; D008962:Models, Theoretical; D004364:Pharmaceutical Preparations / Q000008:administration & dosage / Q000378:metabolism; D010599:Pharmacokinetics; D014481:United States; D014486:United States Food and Drug Administration
D004364:Pharmaceutical Preparations